100000 - Document - Document and Entity Information
link:presentationLink
link:calculationLink
link:definitionLink
100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
100020 - Disclosure - Senior Secured Term Loan Facilities - Summary of Senior Secured Term Loan Facilities (Detail) 2
link:presentationLink
link:calculationLink
link:definitionLink
100030 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
100040 - Statement - Condensed Consolidated Statements of Operations (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
100050 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
100060 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
100070 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
100080 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
995455 - Disclosure - Significant Accounting Policies
link:presentationLink
link:calculationLink
link:definitionLink
995465 - Disclosure - Collaboration Agreements, License Agreement and Revenues
link:presentationLink
link:calculationLink
link:definitionLink
995475 - Disclosure - Variable Interest Entity
link:presentationLink
link:calculationLink
link:definitionLink
995485 - Disclosure - Fair Value Measurements
link:presentationLink
link:calculationLink
link:definitionLink
995495 - Disclosure - Leases
link:presentationLink
link:calculationLink
link:definitionLink
995505 - Disclosure - Balance Sheet Components
link:presentationLink
link:calculationLink
link:definitionLink
995515 - Disclosure - Senior Secured Term Loan Facilities
link:presentationLink
link:calculationLink
link:definitionLink
995525 - Disclosure - Liability Related to Sale of Future Revenues
link:presentationLink
link:calculationLink
link:definitionLink
995535 - Disclosure - Stock-Based Compensation
link:presentationLink
link:calculationLink
link:definitionLink
995545 - Disclosure - At-the-Market Program
link:presentationLink
link:calculationLink
link:definitionLink
995555 - Disclosure - Income Taxes
link:presentationLink
link:calculationLink
link:definitionLink
995565 - Disclosure - Related Party Transactions
link:presentationLink
link:calculationLink
link:definitionLink
995575 - Disclosure - Commitments and Contingencies
link:presentationLink
link:calculationLink
link:definitionLink
995585 - Disclosure - Subsequent Event
link:presentationLink
link:calculationLink
link:definitionLink
995595 - Disclosure - Significant Accounting Policies (Policies)
link:presentationLink
link:calculationLink
link:definitionLink
995605 - Disclosure - Significant Accounting Policies (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995615 - Disclosure - Collaboration Agreements, License Agreement and Revenues (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995625 - Disclosure - Exclusive License and Option to Acquire Fortis Therapeutics (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995635 - Disclosure - Variable Interest Entity (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995645 - Disclosure - Fair Value Measurements (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995655 - Disclosure - Leases (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995665 - Disclosure - Balance Sheet Components (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995675 - Disclosure - Senior Secured Term Loan Facilities (Table)
link:presentationLink
link:calculationLink
link:definitionLink
995685 - Disclosure - Liability Related to Sale of Future Revenues (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995695 - Disclosure - Stock-Based Compensation (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995705 - Disclosure - Significant Accounting Policies - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995715 - Disclosure - Significant Accounting Policies - Schedule of Weighted Impacts of Outstanding Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995725 - Disclosure - Collaboration Agreements, License Agreement and Revenues - Astellas Agreements - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995735 - Disclosure - Collaboration Agreements, License Agreement and Revenues - AstraZeneca Agreements - Additional Information 1 (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995745 - Disclosure - Collaboration Agreements, License Agreement and Revenues - Summary of License Revenue and Development Revenue Recognized under Agreement (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995755 - Disclosure - Collaboration Agreements, License Agreement and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995765 - Disclosure - Collaboration Agreements, License Agreement and Revenues - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995775 - Disclosure - Collaboration Agreements, License Agreement and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations Deferred Revenue (Parenthetical) (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995785 - Disclosure - Collaboration Agreements, License Agreement and Revenues - Summary of Product Revenue, Net (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995795 - Disclosure - Collaboration Agreements, License Agreement and Revenues - Product Revenue, Net - Additional Information 1 (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995805 - Disclosure - Collaboration Agreements, License Agreement and Revenues - Roll-forward of Related Contract Liabilities (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995815 - Disclosure - Collaboration Agreements, License Agreement and Revenues - Drug Product Revenue - Summary of Drug Product Revenue (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995825 - Disclosure - Collaboration Agreements, License Agreement and Revenues - Drug Product Revenue - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995835 - Disclosure - Collaboration Agreements, License Agreement and Revenues - AstraZeneca U.S./RoW Agreement - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995845 - Disclosure - Collaboration Agreements, License Agreement and Revenues - Eluminex Agreement - Additional Information 2 (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995855 - Disclosure - Collaboration Agreements, License Agreement and Revenues - Summary of Amounts Recognized as Revenue (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995865 - Disclosure - Variable Interest Entity - Consolidated Variable Interest Entity - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995875 - Disclosure - Variable Interest Entity - Equity Method Investment - Unconsolidated VIE - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995885 - Disclosure - Variable Interest Entity - Equity Method Investment - Unconsolidated VIE - Summary of Equity Method Investment (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995895 - Disclosure - Fair Value Measurements - Fair Values of Financial Assets Measured on Recurring Basis (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995905 - Disclosure - Fair Value Measurements - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995915 - Disclosure - Balance Sheet Components - Schedule of Cash and Cash Equivalents (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995925 - Disclosure - Balance Sheet Components - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995935 - Disclosure - Balance Sheet Components - Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995945 - Disclosure - Balance Sheet Components - Summary of Available for Sale Securities in Unrealized Loss Position, Fair Value and Gross Unrealized Loss By Length of Time Security in Continual Unrealized Loss Position (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995955 - Disclosure - Balance Sheet Components - Schedule of Inventory (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995965 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995975 - Disclosure - Balance Sheet Components - Schedule of Accrued and Other Current Liabilities (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995985 - Disclosure - Senior Secured Term Loan Facilities - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995995 - Disclosure - Senior Secured Term Loan Facilities - Summary of Senior Secured Term Loan Facilities (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996005 - Disclosure - Liability Related to Sale of Future Revenues - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996015 - Disclosure - Liability Related to Sale of Future Revenues - Schedule of Activities of Liability Related to Sale of Future Revenues (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996025 - Disclosure - Stock-Based Compensation - Schedule of Recorded Stock-Based Compensation Expense (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996035 - Disclosure - Stock-Based Compensation - Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Purchases under 2014 Employee Share Purchase Plan (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996045 - Disclosure - Related Party Transactions - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996055 - Disclosure - Commitments and Contingencies - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996065 - Disclosure - Subsequent Event - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
Variable Interest Entity
Variable Interest Entity Disclosure [Text Block]
Equity method investment - Variable Interest Entity
Collaborative Arrangement and Arrangement Other than Collaborative
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Document Transition Report
Document Transition Report
Expected volatility
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Money market funds [Member]
Money Market Funds [Member]
Description of Operations
Description Of Operations Policy Policy [Text Block]
Description of operations policy.
Clinical and Development Milestone [Member]
Clinical Development Milestones [Member]
Clinical development milestone.
Restructuring plan, expected reduction to workforce, percentage
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent
Basis of Presentation and Principles of Consolidation
Basis Of Presentation And Principles Of Consolidation Policy Policy [Text Block]
Basis of presentation and principles of consolidation policy.
Geographical
Geographical [Axis]
ASC 606 [Member]
Accounting Standards Update 2014-09 [Member]
API Shipment [Member]
A P I Shipment [Member]
API shipment.
HiFiBiO Agreement [Member]
Hi Fi Bi O Agreement [Member]
HiFiBiO agreement.
Noncontrolling Interests [Member]
Noncontrolling Interest [Member]
Revenue resulting from changes to estimated variable consideration
Revenue Resulting from Changes to Estimated Variable Consideration
Revenue resulting from changes to estimated variable consideration.
Related cost of goods sold
Cost of Revenue, Total
Cost of goods sold
Cost of Revenue
Estimated Fair Value
Investments
Fair Value
Debt Securities, Available-for-Sale
Astellas Agreement [Member]
Astellas Collaboration Agreement [Member]
Astellas agreements.
Other long-term liabilities ($2,458 and $656 to a related party)
Total other long-term liabilities
Other Liabilities, Noncurrent
Other long-term liabilities
Nonredeemable non-controlling interests
Nonredeemable Noncontrolling Interest
Increase (Decrease) in Prepaid Expense and Other Assets, Total
Prepaid expenses and other current assets
Increase (Decrease) in Prepaid Expense and Other Assets
Redeemable non-controlling interests
Redeemable Noncontrolling Interest, Equity, Carrying Amount
Redeemable Noncontrolling Interest, Equity, Carrying Amount, Total
Schedule of Lease Assets and Related Lease Liabilities
Schedule Of Lease Assets And Related Lease Liabilities Table [Text Block]
Schedule of lease assets and related lease liabilities.
Level 1 [Member]
Fair Value, Inputs, Level 1 [Member]
Discounted Cash Flow [Member]
Valuation Technique, Discounted Cash Flow [Member]
Fair Value Measurements
Fair Value Disclosures [Text Block]
Drug product revenue recognized
Revenue from Contract with Customer, Excluding Assessed Tax, Total
Total revenue
Revenue from Contract with Customer, Excluding Assessed Tax
Changes in revenue from changes to estimated variable consideration
Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized
Prepaid Expense and Other Assets, Current [Abstract]
Drug Product Revenue, Net [Member]
Drug Product Revenue [Member]
Drug product revenue.
Disaggregation of Revenue [Table Text Block]
Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations and Product Revenue Net
Recently Issued Accounting Guidance Not Yet Adopted
Recently Issued Accounting Guidance Not Yet Adopted Policy [Text Block]
Recently issued accounting guidance not yet adopted.
Schedule of Business Acquisitions, by Acquisition [Table]
Transfers of assets into level 3
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3
Deferred revenue ($7,901 and $7,220 to related parties)
Profit share liability
Deferred Revenue
Schedule of Allocation of Purchase Consideration Based on Estimated Fair Values of Acquired Assets
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]
Available for sale securities in continual unrealized loss position, less than 12 months, estimated fair value
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months
Subsequent Events [Text Block]
Subsequent Event
Equity Method Investment, Nonconsolidated Investee
Equity Method Investment, Nonconsolidated Investee [Axis]
Biosynthetic Cornea.
biosynthetic Cornea [Member]
Biosynthetic Cornea [Member]
Accrued interest
Debt Instrument Accrued Interest
Debt instrument accrued interest.
Operating lease liabilities
Operating lease liabilities, non-current
Operating Lease, Liability, Noncurrent
Unrestricted cash and cash equivalent balance required to maintain in accounts
Unrestricted Cash And Cash Equivalent Balance Maintain In Accounts
Unrestricted cash and cash equivalent balance maintain in accounts.
Commercial sales and other events milestone
Commercial Sales And Other Events Milestone
Commercial sales and other events milestone.
Europe [Member]
Europe [Member]
API and bulk drug product price true-up
Accrued API and bulk drug product price true-up current
Accrued API and bulk drug product price true-up current.
Reduction of drug product revenue from related party
Reduction Of Drug Product Revenue From Related Party
Reduction of drug product revenue from related party.
Collaboration Agreements, License Agreement and Revenues
Collaborative Arrangements License Agreement And Revenues Policy [Text Block]
Collaborative arrangements license agreement and revenues.
Number of identified performance obligation at inception of agreement
Number Of Identified Performance Obligation At Inception Of Agreement
Number of identified performance obligation at inception of agreement.
Related Party Transactions [Abstract]
Balance Sheet Location
Balance Sheet Location [Axis]
Payment cap date on or after January one two thousand twenty nine.
Payment cap date on or after January one two thousand twenty nine [Member]
Payment Cap Date on or after January 1, 2029 [Member]
Total current assets
Assets, Current
Issuance costs, amortised
Accumulated Amortization, Debt Issuance Costs
Total liabilities, redeemable non-controlling interests and deficit
Liabilities and Equity
Proceeds from sales of available-for-sale securities
Proceeds From Sales Of Available For Sale Securities
Proceeds from sales of available for sale securities
Entity Address, State or Province
Entity Address, State or Province
Percentage of product manufacturing costs until manufacturing technology fully transferred
Percentage Of Product Manufacturing Costs Until Manufacturing Technology Fully Transferred
Percentage of product manufacturing costs until manufacturing technology fully transferred.
Transaction
Transaction [Domain]
Transfers of assets from level 2 to 1
Fair Value Assets Level2 To Level1 Transfer Amount
Fair value assets level2 to level1 transfer amount.
Stock Issued During Period, Value, New Issues
Issuance of common stock under ATM Program
Weighted average estimated fair value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive loss
Trading Symbol
Trading Symbol
Common Stock, Shares, Issued, Total
Common stock, shares issued
Common Stock, Shares, Issued
Schedule of Available-for-sale Securities [Line Items]
Debt Securities, Available-for-Sale [Line Items]
Operating costs and expenses:
Operating Costs and Expenses [Abstract]
Revenue Interest Financing Agreement.
Revenue Interest Financing Agreement [Member]
Accounts receivable net current related parties.
Accounts Receivable Net Current Related Parties
Accounts receivable from related parties
Aggregate considerations received
Collaborative Arrangement Aggregate Consideration
Collaborative arrangement aggregate consideration.
Prepaid expenses and other current assets
Total prepaid expenses and other current assets
Prepaid Expense and Other Assets, Current
Deduction
Contract With Customer Liability Deduction
Contract with customer liability deduction.
Payments for transaction costs related to sale of future revenues.
Payments For Transaction Costs Related To Sale Of Future Revenues
Transaction costs related to sale of future revenues
Cash paid for transaction costs for senior secured term loan facilities
Repayments of Secured Debt
Repayments of finance lease liabilities
Financing cash flows from finance leases
Repayments Of Finance Lease Liabilities
Repayments of finance lease liabilities.
Schedule of Long-Term Debt Instruments [Table]
Balance, Shares
Balance, Shares
Shares, Outstanding
Accumulated Other Comprehensive Income (Loss) [Member]
AOCI Attributable to Parent [Member]
Other Comprehensive Income (Loss), Net of Tax
Other comprehensive gain (loss), net of taxes
Repayment description
Repayment Description
Repayment description.
Contract Liabilities [Member]
Contract Liabilities [Member]
Contract liabilities,
Operating lease liabilities, current
Increase Decrease In Operating Lease Liabilities Current
Increase (decrease) in operating lease liabilities, current.
Summary of Equity Method Investment
Equity Method Investments [Table Text Block]
Entity Address, City or Town
Entity Address, City or Town
Related Party Transaction [Line Items]
Related Party Transaction [Line Items]
Deferred revenue non-current to related party
Due To Related Parties Deferred Revenue Noncurrent
Due to related parties deferred revenue noncurrent.
Senior Secured Term Loan Facilities
Debt Disclosure [Text Block]
Other Revenue - Contract Manufacturing [Member]
Development Revenue [Member]
Development and Other Revenue [Member]
Development and other revenue.
Product development obligations
Accrued Product Development Costs
Represents the long-term portion of the outstanding principal and accrued interest of advances in the form note agreements received by the entity to fund various product development efforts.
Subsequent Event [Member]
Subsequent Event Type [Axis]
Other liabilities current due to related parties.
Other Liabilities Current Due to Related Parties
Accrued and other current liabilities to related party
Additional Paid-in Capital [Member]
Additional Paid-in Capital [Member]
Inventory, Raw Materials, Gross, Total
Raw materials
Inventory, Raw Materials, Gross
Current liabilities:
Liabilities, Current [Abstract]
Cash acquired from consolidation of Fortis
Cash Acquired from Acquisition
Available for sale securities in continual unrealized loss position, 12 months or more, estimated fair value
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer
Current assets:
Assets, Current [Abstract]
Counterparty Name [Axis]
Preferred stock, par value
Preferred Stock, Par or Stated Value Per Share
Statement of Stockholders' Equity [Abstract]
Debt financing agreement.
Debt Financing Agreement [Member]
Operating lease liabilities
Operating lease liabilities, current
Operating Lease, Liability, Current
Maturity date
Debt Instrument, Maturity Date
Senior secured term loan facilities, ending balance
Term loan
Long-Term Debt
Property, Plant and Equipment, Net, Ending Balance
Property, Plant and Equipment, Net, Beginning Balance
Property and equipment, net
Property and equipment, net
Property, Plant and Equipment, Net
Series A Preferred Shares [Member]
Series A Preferred Stock [Member]
Class of Stock [Domain]
Restructuring plan, non-recurring charges
Restructuring Charges
Restructuring Charges, Total
Restructuring charge
Liability related to sale of revenues noncurrent.
Liability Related To Sale Of Revenues NonCurrent
Liability related to sale of future revenues, non-current
Statement of Comprehensive Income [Abstract]
Collaborative Arrangement and Arrangement Other than Collaborative
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Entity Central Index Key
Entity Central Index Key
U.S. government bonds [Member]
US Treasury and Government [Member]
Loss on disposal of property and equipment
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property
Loss on disposal of property and equipment
Total fair value of financial assets
Assets, Fair Value Disclosure
Assets, Fair Value Disclosure, Total
Increase (Decrease) in Other Operating Assets, Total
Other assets
Increase (Decrease) in Other Operating Assets
Preferred Stock, Shares Outstanding, Ending Balance
Preferred Stock, Shares Outstanding, Beginning Balance
Preferred stock, shares outstanding
Preferred Stock, Shares Outstanding
Less: Current Portion classified to accrued and other current liabilities
Current Portion Classified to Accrued and Other Current Liabilities
Current portion classified to accrued and other current liabilities.
Total current liabilities
Liabilities, Current
Entity Tax Identification Number
Entity Tax Identification Number
Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]
Additional consideration based on net sales description
Additional Consideration Based On Net Sales
The amount of additional consideration based on net sales of product as defined under a collaboration agreement.
Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Purchases under 2014 Employee Share Purchase Plan
Schedule Of Share Based Payment Award Stock Options And Employee Stock Purchase Plan Valuation Assumptions Table [Text Block]
Schedule of share based payment award stock options and employee stock purchase plan valuation assumptions.
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Changes in operating assets and liabilities:
Increase (Decrease) in Operating Capital [Abstract]
Property taxes and other taxes
Property Taxes And Other Current
Property taxes and other current.
Financial Instruments [Domain]
Additional upfront payments
Collaborative Arrangement Additional Upfront Payments
Collaborative arrangement additional upfront payments.
License and milestone revenue from a related party
License Fees And Milestones Revenue
Revenue from multiple-deliverable arrangements that include licensing fees and services revenue and the amount of consideration recognized during the period for milestones. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, non-specified, services during the reporting period.
Award Date [Domain]
Weighted average number of common shares used to calculate net loss per share:
Weighted average shares used to compute net income (loss) per share:
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Investment, Name [Axis]
Shares issued from stock plans
Stock Issued During Period, Value, Employee Stock Purchase Plan
Deferred revenues from associated contracts
Deferred Revenues From Associated Contracts
Deferred revenues from associated contracts.
Initial Term Loan [Member]
Initial Term Loan [Member]
Initial Term Loan [Member]
Cash and Cash Equivalents [Abstract]
Miscellaneous receivables
Miscellaneous Receivables
Miscellaneous receivables.
Equity Method Investment, Nonconsolidated Investee
Equity Method Investment, Nonconsolidated Investee [Domain]
Geographical
Geographical [Domain]
Total assets
Assets
U.S. [Member]
UNITED STATES
Operating lease right-of-use assets, net
Operating lease right-of-use assets
Operating Lease, Right-of-Use Asset
Non-cash interest expense related to drug product revenue
Non-cash interest expense related to drug product revenue
Non-cash interest expense related to drug product revenue
Accrued and other liabilities
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Reduction of accrued and other current liabilities
Gross proceeds received from sale of revenue.
Gross proceeds received from sale of revenue
Gross proceeds received from sale of revenue
Entity Registrant Name
Entity Registrant Name
Asset-backed securities [Member]
Asset-Backed Securities [Member]
Issuance cost
Debt Issuance Costs, Net
Debt Issuance Costs, Net, Total
Related Party
Related Party, Type [Domain]
Retained Earnings (Accumulated Deficit), Ending Balance
Retained Earnings (Accumulated Deficit), Beginning Balance
Retained Earnings (Accumulated Deficit), Total
Accumulated deficit
Retained Earnings (Accumulated Deficit)
Available for sale securities in continual unrealized loss position, less than 12 months, gross unrealized holding losses
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss
Prepayment amount.
Prepayment amount
Prepayment amount of 2024 to 2030
Commercial milestone
Commercial Milestone
Commercial milestone.
Accumulated Deficit [Member]
Retained Earnings [Member]
Class of Stock [Axis]
Balance
Balance
Equity, Including Portion Attributable to Noncontrolling Interest
Total deficit
Shares issued from stock plans, Shares
Stock Issued During Period, Shares, Employee Stock Purchase Plans
Minimum [Member]
Minimum [Member]
Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Investments
Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]
Agency bonds [Member]
Bonds [Member]
Revenues, Total
Revenues
Revenues from related parties
Significant Accounting Policies
Significant Accounting Policies [Text Block]
Schedule of Prepaid Expenses and Other Current Assets
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]
Operating Lease, Liability, Total
Present value of lease liabilities
Operating lease liability
Operating Lease, Liability
Expected volatility, minimum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum
Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member]
Beijing Kangda Yongfu Pharmaceutical Co L T D [Member]
Beijing Kangda Yongfu Pharmaceutical Co., LTD.
Disaggregation of Revenue [Abstract]
Equity Component
Equity Component [Domain]
Employee stock options [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Less: Unamortized issuance costs
Less: Unamortized issuance costs
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total
Measurement Frequency
Measurement Frequency [Axis]
Debt Disclosure [Abstract]
Entity Current Reporting Status
Entity Current Reporting Status
Common stock, shares authorized
Common Stock, Shares Authorized
Research and Development Expense, Total
Research and development
Research and Development Expense
Acquired in-process research and development expenses
Contract With Customer Liability [Table]
Contract With Customer Liability [Table]
Contract With Customer Liability [Table]
Finance lease right-of-use assets
Finance lease right-of-use assets, net
Finance lease right-of-use assets
Finance Lease, Right-of-Use Asset, after Accumulated Amortization
U.S./RoW [Member]
United States And Rest Of World [Member]
United states and rest of world.
Assets
Assets [Abstract]
Upfront, non-contingent, non-refundable and time-based payments
Proceeds From Upfront Non Contingent Non Refundable And Time Based Payments
Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration.
Proceeds from Issuance of Common Stock
Proceeds from issuance of common stock under employee stock plans
Proceeds from sale of common stock
AstraZeneca U.S./RoW Agreement [Member]
AstraZeneca U.S./RoW agreement member.
Balance Presented Net Against Contract Asset
Contract with customer liability net of balance presented against contract asset
Contract with customer liability net of balance presented against contract asset.
Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]
Common stock, $0.01 par value; 225,000 shares authorized at March 31, 2024 and December 31, 2023; 99,474 and 98,770 shares issued and outstanding at March 31, 2024 and December 31, 2023
Common Stock, Value, Issued, Ending Balance
Common Stock, Value, Issued, Beginning Balance
Common Stock, Value, Issued, Total
Common Stock, Value, Issued
Net Transfer Price [Member]
Net Transfer Price [Member]
Net transfer price.
Discounts and Rebates [Member]
Discounts And Rebates [Member]
Discounts and rebates.
Proceeds from sale of property and equipment
Proceeds from Sale of Property, Plant, and Equipment
Proceeds from Sale of Property, Plant, and Equipment, Total
Decrease (Increase) in Deferred Revenue [Member]
Increase decrease in deferred revenue.
Increase Decrease In Deferred Revenue [Member]
Royalty revenue recognized as drug product revenue
Recognized as Revenue
Contract with Customer, Liability, Revenue Recognized
Total accrued and other current liabilities
Accrued Liabilities, Current
Percentage of revenue interest on global net sales.
Percentage Of Revenue Interest On Global Net Sales
Percentage of revenue interest on global net sales
Current Fiscal Year End Date
Current Fiscal Year End Date
Share-based Payment Arrangement, Noncash Expense, Total
Stock-based compensation
Share-Based Payment Arrangement, Noncash Expense
Operating Income (Loss)
Loss from operations
SEC Schedule, 12-09, Valuation Allowances and Reserves Type
SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]
Co-development, information sharing & committee services [Member]
Co Development Information Sharing And Committee Services [Member]
Co development information sharing and committee services.
Schedule of Maturities of Finance and Operating Leases Liabilities
Schedule Of Maturities Of Finance And Operating Leases Liabilities Table [Text Block]
Schedule of maturities of finance and operating leases liabilities.
Purchase consideration
Business Combination, Consideration Transferred
Business Combination, Consideration Transferred, Total
Commitments And Contingencies [Line Items]
Commitments And Contingencies [Line Items]
Commitments and contingencies.
Provision for income taxes
Income Tax Expense (Benefit), Total
Provision for income taxes
Income Tax Expense (Benefit)
Litigation settlement receivable
Insurance proceeds receivable for litigation settlement
Loss Contingency, Receivable, Current
Research and development [Member]
Research and Development Expense [Member]
Milestone payments.
Milestone payments [Member]
Consolidation of Fortis (Note 3)
Stock Issued During Period, Shares, Acquisitions
Cash, Ending Balance
Cash, Beginning Balance
Cash
Cash
Payments for Restructuring
Cash payments for restructuring
Royalty [Member]
Royalty Revenue [Member]
Total stock-based compensation expense
Share-Based Payment Arrangement, Expense
Expected volatility, maximum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
Cash paid for payroll taxes on restricted stock unit releases
Payment, Tax Withholding, Share-Based Payment Arrangement
Disaggregation Of Revenue [Table]
Disaggregation of Revenue [Table]
Measurement Input Type [Domain]
Long-term portion of lease obligations
Lease Obligations Non-Current
Lease obligations non-current.
Deferred revenue
Deferred Revenue
Deferred Revenue, Total
Valuation Approach and Technique [Domain]
Other comprehensive income (loss):
Other Comprehensive Income (Loss), Net of Tax [Abstract]
License [Member]
License Revenue [Member]
License [Member]
NovaQuest Capital Management [Member]
NovaQuest Capital Management.
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Net Loss per Share
Net Income (Loss) per Share
Earnings Per Share, Policy [Policy Text Block]
Other
Other Nonoperating Income (Expense)
Other Nonoperating Income (Expense), Total
Deferred revenue current to related party
Due To Related Parties Deferred Revenue Current
Due to related parties deferred revenue current.
Drug product revenue from a related party
Drug Product Revenue From Related Party
Drug product revenue from related party.
Deferred Approval Milestone [Member]
Deferred Approval Milestone [Member]
Deferred approval milestone.
Long-Term Debt, Type [Domain]
Astra Zeneca [Member]
AstraZenecaAB [Member]
AstraZeneca AB.
Recently Issued and Adopted Accounting Guidance
Recently Issued And Adopted Accounting Guidance Policy [Text Block]
Recently issued and adopted accounting guidance.
Subsequent Events [Abstract]
Maximum payment cap amount.
Maximum payment cap amount
Maximum payment cap amount
US Government Securities, at Carrying Value
U.S. government bonds
Other liabilities noncurrent due to related parties.
Other Liabilities Noncurrent Due to Related Parties
Due to related parties, noncurrent
Commitments and Contingencies Disclosure [Abstract]
Other Assets, Noncurrent, Total
Other assets
Other Assets, Noncurrent
Other
Other Accrued Liabilities, Current
Equity [Text Block]
At-the-Market Program
Depreciation, Total
Depreciation
Depreciation
Fair value of U.S. treasury notes and bills transfered from level 1 to level 2
Fair value of US treasury notes and bills transfered from level one to level two.
Fair Value Of US Treasury Notes And Bills Transfered From Level One To Level Two
Astellas Agreement [Member]
Astellas Agreement [Member]
Astellas agreement.
Discount rate applied
Alternative Investment, Measurement Input
Summary of Amounts Recognized as Revenue
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]
Additional Paid in Capital, Ending Balance
Additional Paid in Capital, Beginning Balance
Additional Paid in Capital, Total
Additional paid-in capital
Additional Paid in Capital
Currency Translation
Equity Method Investment Increase Decrease From Currency Translation
Equity method investment increase (decrease) from currency translation.
Manufacture and Supply of Pamrevlumab [Member]
Manufacture And Supply Of Pamrevlumab [Member]
Manufacture and supply of pamrevlumab.
Commitments And Contingencies [Table]
Commitments And Contingencies [Table]
Commitments and contingencies.
Gross Unrealized Holding Gains
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Operating lease right-of-use assets
Increase Decrease In Operating Lease Right Of Use Assets
Increase (decrease) in operating lease right-of-use assets.
Accrued interest expense related to sale of future revenues
Increase Decrease In Accrued Interest Expense Related To Sale Of Future Revenues
Increase (decrease) in accrued interest expense related to sale of future revenues
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Components of Lease Expense
Lease, Cost [Table Text Block]
Related accounts receivable
Related accounts receivable
Related Accounts Receivable
Related accounts receivable.
Commercial sales milestone
Commercial Sales Milestone
Represents the amount of milestone payments related to commercial sales under the collaborative agreement.
Repayments of lease obligations
Repayments of Debt and Lease Obligation
Received from sale of revenue.
Received From Sale of Revenue
Received from sale of revenue
Liability related to sale of revenue current.
Liability Related To Sale Of Revenue Current
Less: Current portion classified to accrued and other current liabilities
Earnings Per Share [Abstract]
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total
Change in unrealized gain or loss on investments
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax
Investment, Name [Domain]
Total Consideration
Cash Consideration Received Under Collaboration Agreement
The total cash consideration received under a collaboration agreement that has been allocated to the different significant units of accounting and includes the portion that has been deferred for revenue recognition.
Accounting Policies [Abstract]
Sales Returns [Member]
Sales Returns and Allowances [Member]
Constrained for Future Recognition [Member]
Deferred For Future Recognition [Member]
Deferred for future recognition.
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Payment to options exercised
Payment to Options Exercised
Payment to options exercised
Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Stockholders' deficit:
Net loss per share - basic
Basic
Earnings Per Share, Basic, Total
Earnings Per Share, Basic
Asset Acquisition
Asset Acquisition Policy [Policy Text Block]
Asset acquisition policy.
Inventory write-down
Inventory write-down
Inventory Write-down
Commitments and Contingencies (Note 12)
Commitments and Contingencies
Regulatory Milestone [Member]
Regulatory Milestones [Member]
Regulatory milestone.
Business Combinations [Abstract]
Acquisition And Variable Interest Entity [Abstract]
Acquisition and variable interest entity abstract.
Income Statement [Abstract]
China performance obligation [Member]
China Performance Obligation [Member]
China performance obligation.
Related Party
Related Party, Type [Axis]
Roll-forward of Related Contract Liabilities
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]
Measurement Input Type [Axis]
Statistical Measurement
Statistical Measurement [Domain]
Net cash used in operating activities
Net Cash Provided by (Used in) Operating Activities
Astellas Europe Agreement.
Astellas Europe Agreement [Member]
Astellas Europe Agreement [Member]
Accrued co-promotion expenses - current
Accrued Co Promotion Expenses Current
Accrued co-promotion expenses - current.
Non cash interest expense related to sale of future revenues.
Non Cash Interest Expense Related To Sale Of Future Revenues
Non-cash interest expense related to sale of future revenues
Interest expense recognized
Document Period End Date
Document Period End Date
Statistical Measurement
Statistical Measurement [Axis]
Accounts Receivable, Allowance for Credit Loss, Ending Balance
Accounts Receivable, Allowance for Credit Loss, Beginning Balance
Reductions to gross accounts receivable
Accounts Receivable, Allowance for Credit Loss
Commitments and Contingencies
Commitments and Contingencies Disclosure [Text Block]
Stockholders' Equity Note [Abstract]
Cornea Products [Member]
Cornea Products [Member]
Cornea products.
Investment Income, Dividend
Dividend received
Dividend Received
Dividend Received
Net loss per share - diluted
Diluted
Earnings Per Share, Diluted, Total
Earnings Per Share, Diluted
Product Development Costs
Product Development Costs
Product development obligations
Product and Service
Product and Service [Domain]
Mark Eisner.
Mark Eisner [Member]
Contract with customer liability increase decrease in revenue due to changes to estimated variable consideration.
Contract With Customer Liability Increase Decrease In Revenue Due To Changes To Estimated Variable Consideration
Contract with customer liability increase decrease in revenue due to changes to estimated variable consideration
SEC Schedule, 12-09, Valuation Allowances and Reserves
SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]
Revenue:
Revenue from Contract with Customer [Abstract]
Delayed draw term loan.
Delayed Draw Term Loan [Member]
Debt Instrument, Name [Domain]
Fair Value Hierarchy and NAV
Fair Value Hierarchy and NAV [Domain]
Product Revenue, Net
Product Revenue Policy Policy [Text Block]
Product revenue policy.
Loss before income taxes
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest
Loss before income taxes
Drug Product Revenue
Drug Product Revenue Policy [Text Block]
Drug product revenue.
Other long-term liabilities
Increase (Decrease) in Other Noncurrent Liabilities
Interest paid
Interest Paid Related to Sale of Future Revenues
Interest paid related to sale of future revenues.
China [Member]
CHINA
Development and regulatory approval milestones
Development And Regulatory Approval Milestones
Represents the potential amount of milestone payments related to development and regulatory approval under the collaborative agreement.
Fair Value, Measurements, Recurring [Member]
Fair Value, Recurring [Member]
Profit Share [Member]
Profit Share [Member]
Profit share.
Number of reportable segment
Number of Reportable Segments
Non-cash interest expense related to sale of future revenues
Non-cash change in accrued interest expense and payments related to sale of future revenues
Non-cash change in accrued interest expense and payments related to sale of future revenues.
Liability related to sale of future revenue.
Liability Related To Sale of Future Revenue [Text Block]
Liability Related to Sale of Future Revenues
Nonredeemable [Member]
Nonredeemable Preferred Stock [Member]
Other revenue patent transfer .
Other Revenue Patent Transfer [Member]
Other Revenue - Patent Transfer [Member]
Finite-Lived Intangible Assets, Major Class Name
Finite-Lived Intangible Assets, Major Class Name [Domain]
Accrued restructuring charges.
Accrued Restructuring Charges
Accrued restructuring charges
Shares issued from stock plans, net of payroll taxes paid, Shares
Shares Issued From Stock Plans Net Of Payroll Taxes Paid Shares
Shares issued from stock plans net of payroll taxes paid shares.
Long-term investments
Long Term Investment Excluding Equity Method Investments
Long term investment excluding equity method investments.
Liabilities, redeemable non-controlling interests and deficit
Liabilities and Equity [Abstract]
Potential milestone payments
Potential Milestones
Represents the total potential amount of milestone payments related to development, regulatory approval and commercial sales under the collaborative agreement.
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Entity Interactive Data Current
Entity Interactive Data Current
Sales and marketing
Selling and Marketing Expense
Selling and Marketing Expense, Total
Measurement Input Discount Rate [Member]
Measurement Input, Discount Rate [Member]
Increase (Decrease) in Accounts Payable, Total
Accounts payable
Increase (Decrease) in Accounts Payable
Summary of Available for Sale Securities in Unrealized Loss Position, Fair Value and Gross Unrealized Loss By Length of Time Security in Continual Unrealized Loss Position
Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]
Billed Contracts Receivable
Payment made for acquired in-process research and development asset
Payments to Acquire in Process Research and Development
Upfront, non-contingent and time-based payments received
Proceeds From Upfront Non Contingent And Time Based Payments
Represents the amount of fixed and determinable non-contingent upfront payments included under the collaborative agreement as arrangement consideration.
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Fair value of the acquired IPR&D assets
Fair value of the acquired in process research and development assets
Fair value of the acquired in process research and development assets.
Drug Product Revenue, Net [Member]
Drug product revenue, net.
Equity Components
Equity Components [Axis]
Convertible promissory note.
Convertible promissory note [Member]
Convertible promissory note [Member]
Accounts receivable, net
Increase (Decrease) in Accounts Receivable
Investments, Debt and Equity Securities [Abstract]
Maximum future milestone payments
Maximum Future Milestone Payments
Maximum future milestone payments.
Future revenue granted.
Future revenue granted
Future revenue granted
Collaboration services and other revenue from a related party
Collaboration Services And Other Revenue
Revenue recognized from co-development services, manufacturing of clinical supplies, committee services and information services and other revenue.
Proceeds from Sale, Maturity and Collection of Investments, Total
Proceeds from maturities of investments
Proceeds from Sale, Maturity and Collection of Investments
Senior secured term loan facilities, non-current
Secured Long-Term Debt, Noncurrent
Local Phone Number
Local Phone Number
Payment cap date on or before December thirty one two thousand twenty eight.
Payment cap date on or before December thirty one two thousand twenty eight [Member]
Payment Cap Date on or before December 31, 2028 [Member]
Collaboration Agreements, License Agreement and Revenues
Collaborative arrangement and revenues.
Collaborative Arrangement And Revenues Disclosure [Text Block]
AstraZeneca Agreements [Member]
Astra Zeneca Agreements [Member]
Astra Zeneca agreements.
Number of complaints filed
Putative securities class action complaints filed
Loss Contingency, New Claims Filed, Number
Statement of Cash Flows [Abstract]
Available-for-sale investments:
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax [Abstract]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated Other Comprehensive Income (Loss), Net of Tax, Total
Accumulated other comprehensive loss
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accrued restructuring charge current.
Accrued Restructuring Charge Current
Accrued restructuring charge
Milestone payments.
Milestone Payments
Milestone payments
Preclinical and clinical trial accruals
Accrued Preclinical And Clinical Trial Current
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to pre-clinical and clinical trial activities, including those performed by third parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Common stock, par value
Common Stock, Par or Stated Value Per Share
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total
Effect of exchange rate change on cash and cash equivalents
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
Total interest and other, net
Interest Income (Expense), Nonoperating, Net
Senior Secured Term Loan Facilities [Member]
Senior secured term loan facilities.
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Effective Annual Interest Rate Related To Sale Of Future Revenues
Effective Annual Interest Rate Related To Sale Of Future Revenues
Effective annual interest rate related to sale of future revenues
Maximum [Member]
Maximum [Member]
Christine Chung.
Christine Chung [Member]
Unbilled upfront payment
Aggregate consideration received for milestone and upfront payments
Collaborative Arrangement Aggregate Consideration For Milestone And Upfront Payments
Collaborative arrangement aggregate consideration for milestone and upfront payments.
Contract with Customer Liability [Line Items]
Contract With Customer Liability [Line Items]
Contract with customer liability.
Accrued inventory related cost
Inventory cost related
Accrued Inventory Cost
Accrued inventory cost.
Schedule of Investments [Abstract]
Level 3 [Member]
Fair Value, Inputs, Level 3 [Member]
APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total
Stock-based compensation
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Fair Value, Recurring and Nonrecurring [Table]
Ownership [Domain]
Net increase (decrease) in cash and cash equivalents
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Payment cap date after January one two thousand thirty.
Payment cap date after January one two thousand thirty [Member]
Payment Cap Date after January 1, 2030 [Member]
Fortis Therapeutics [Member]
Fortis Therapeutics [Member]
Fortis Therapeutics.
Related accrued liabilities
Accrued liabilities
Accrued Liabilities
Accrued Liabilities, Total
Schedule of Lease Term and Discount Rate
Schedule Of Lease Term And Discount Rate Table [Text Block]
Schedule of lease term and discount rate.
Schedule of Weighted Impacts of Outstanding Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Schedule of Inventory
Schedule of Inventory, Current [Table Text Block]
Agency bonds [Member]
Agency Bonds [Member]
Agency bonds.
Operating lease liabilities, non-current
Increase Decrease In Operating Lease Liabilities Non Current
Increase (decrease) in operating lease liabilities, non-current.
City Area Code
City Area Code
Research and Development Arrangement, Contract to Perform for Others, Type
Research and Development Arrangement, Contract to Perform for Others, Type [Axis]
Total inventories
Inventories
Inventory, Net
Operating activities
Net Cash Provided by (Used in) Operating Activities [Abstract]
Accounting Policy [Line Items]
Accounting Policy [Line Items]
Accounting policy.
Interest income
Interest Income, Other
Payment Period One [Member]
Payment Period One [Member]
Restricted Cash and Cash Equivalents, Noncurrent, Total
Restricted time deposits
Restricted Cash and Cash Equivalents, Noncurrent
Business Acquisition [Line Items]
Acquisition And Variable Interest Entity [Table]
Acquisition And Variable Interest Entity [Table]
Acquisition and variable interest entity table.
Litigation settlement current.
Litigation Settlement Current
Litigation settlement
Gross Accounts Receivable [Member]
Gross Accounts Receivable [Member]
Gross accounts receivable.
General and administrative
General and Administrative Expense
General and Administrative Expense, Total
Japan [Member]
JAPAN
Selling, general and administrative [Member]
Selling, General and Administrative Expenses [Member]
Realized loss on sales of available-for-sale securities
Realized loss on sales of available-for-sale securities
Debt Securities, Available-for-Sale, Realized Gain (Loss), Excluding Other-than-temporary Impairment
Debt Securities, Available-for-sale, Realized Gain (Loss), Excluding Other-than-temporary Impairment, Total
Basic
Basic
Weighted Average Number of Shares Outstanding, Basic, Total
Weighted Average Number of Shares Outstanding, Basic
Falikang [Member]
Falikang [Member]
Falikang.
Research and Development Arrangement, Contract to Perform for Others, Type
Research and Development Arrangement, Contract to Perform for Others, Type [Domain]
Work-in-progress
Inventory, Work in Process, Gross
ESPP [Member]
Employee Stock [Member]
E U Supply And Astellas Agreement [Member]
E U supply and Astellas agreement.
Financing activities
Net Cash Provided by (Used in) Financing Activities [Abstract]
Rebates and Discounts [Member]
Rebates And Discounts [Member]
Rebates and discounts.
Statement [Table]
Statement [Table]
Schedule Of Related Party Transactions By Related Party [Table]
Schedule of Related Party Transactions, by Related Party [Table]
Deferred revenue
Increase (Decrease) in Contract with Customer, Liability
Development revenue.
Development Revenue [Member]
Document Fiscal Period Focus
Document Fiscal Period Focus
Other Investors [Member]
Other investors.
Investment income
Investment income (loss)
Share of Net Income
Income (Loss) from Equity Method Investments, Total
Investment income in unconsolidated variable interest entity
Related Party Transactions
Related Party Transactions Disclosure [Text Block]
Professional services
Accrued Professional Fees, Current
Statement [Line Items]
Statement [Line Items]
Summary of Senior Secured Term Loan Facilities
Schedule of Long-Term Debt Instruments [Table Text Block]
Summary of License Revenue and Development Revenue Recognized under Agreement
Contract With Customer Milestone Method Table [Text Block]
Contract with customer milestone method.
Anti-dilutive securities excluded from computation of net loss per share
Anti-dilutive shares outstanding
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Less: Unamortized issuance costs and transaction costs
Less: Unamortized issuance costs and transaction costs
Unamortized Issuance Costs and Transaction Costs
Unamortized issuance costs and transaction costs.
Subsequent Event [Line Items]
Shares issued from stock plans, net of payroll taxes paid
Adjustments To Additional Paid In Capital Shares Issued From Stock Plans Net Of Payroll Taxes Paid
Adjustments to additional paid in capital shares issued from stock plans net of payroll taxes paid.
Future manufacturing clinical regulatory and commercial milestone payments
Future Manufacturing Clinical Regulatory And Commercial Milestone Payments
Future manufacturing clinical regulatory and commercial milestone payments.
Accounts receivable, net ($7,122 and $6,079 from related parties)
Accounts Receivable, after Allowance for Credit Loss, Current, Total
Accounts Receivable, after Allowance for Credit Loss, Current
Accounts receivable from related parties
Common Stock [Member]
Common Stock [Member]
Debt Instrument [Line Items]
Direct Sales [Member]
Direct Sales [Member]
Direct sales.
Cash and Cash Equivalents, at Carrying Value, Ending Balance
Cash and Cash Equivalents, at Carrying Value, Beginning Balance
Total cash and cash equivalents
Cash and cash equivalents
Cash and Cash Equivalents, at Carrying Value
Schedule of Recorded Stock-Based Compensation Expense
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
Other current assets
Other Assets, Current
Corporate bonds [Member]
Corporate Bond Securities [Member]
Net accretion of premium and discount on investments
Accretion (Amortization) of Discounts and Premiums, Investments
Prepaid assets
Prepaid Expense, Current
Prepaid Expense, Current, Total
Entity Common Stock Shares Outstanding
Entity Common Stock, Shares Outstanding
Accounts Payable, Total
Accounts Payable
Accounts payable
Loss Contingency Accrual, Beginning Balance
Loss Contingency Accrual, Ending Balance
Loss Contingency Accrual
Litigation settlement amount
Inventory, Finished Goods, Gross, Total
Finished goods
Inventory, Finished Goods, Gross
Antidilutive Securities, Name [Domain]
Revenue interest payment.
Revenue interest payment
Revenue interest payment
Additional upfront payments
Collaborative Arrangement Additional Upfront Amount
Collaborative arrangement additional upfront Amount.
Acquisition And Variable Interest Entity [Line Items]
Acquisition And Variable Interest Entity [Line Items]
Acquisition and variable interest entity line items.
Beijing Falikang Pharmaceutical Co. Ltd [Member]
Beijing Falikang Pharmaceutical Co Ltd
Beijing Falikang Pharmaceutical Co Ltd [Member]
Beijing Falikang Pharmaceutical Co. Ltd.
Cover [Abstract]
Selling, General and Administrative Expense, Total
Selling, general and administrative
Selling, General and Administrative Expense
Long-term Purchase Commitment, Category of Item Purchased
Long-Term Purchase Commitment, Category of Item Purchased [Domain]
Document Fiscal Year Focus
Document Fiscal Year Focus
Liability related to sale of future revenues non current.
Liability Related To Sale Of Future Revenues Non Current
Liability related to sale of future revenues, non-current
Transfers of assets out of level 3
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3
Fair value of US treasury notes and bills transfered from level one to level two.
Fair Value Of Us Treasury Notes And Bills Transfered From Level One To Level Two1
Fair value of U.S. treasury notes and bills transfered from level 1 to level 2
Research And Pre Clinical Stage Development Programs [Member]
Research and pre-clinical stage development programs.
Research and Preclinical Stage Development Programs [Member]
Stock-Based Compensation
Share-Based Payment Arrangement [Policy Text Block]
Net contract assets
Net unbilled co-development revenue
Supplies Net
Supplies, net.
Net unbilled milestone and co-development revenue
Aggregate consideration received excluding drug product revenue
Collaborative Arrangement Aggregate Consideration Excluding Drug Product Revenue
Amount of aggregate consideration receivable under collaborative arrangement excluding drug product revenue.
RSUs, PRSUs and TSR Awards [Member]
RSUs, PRSUs and TSR Awards [Member]
RSUs, PRSUs and TSR awards [Member]
Bond and mutual funds [Member]
Bond And Mutual Funds [Member]
Bond and mutual funds.
Security Exchange Name
Security Exchange Name
Schedule of Cash and Cash Equivalents
Schedule of Cash and Cash Equivalents [Table Text Block]
Preferred Stock, Shares Issued, Total
Preferred stock, shares issued
Preferred Stock, Shares Issued
Preferred stock, shares authorized
Preferred Stock, Shares Authorized
Third Party Shareholders [Member]
Third party shareholders.
Proceeds from upfront, non-contingent and non-refundable payments
Proceeds From Upfront Non Contingent And Non Refundable Payments
Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration.
Business Acquisition, Acquiree
Business Acquisition, Acquiree [Domain]
Upfront payment
Upfront Payment
Upfront payment.
Financial Instrument [Axis]
Entity Emerging Growth Company
Entity Emerging Growth Company
Percentage of outstanding shares acquired
Business Acquisition, Percentage of Voting Interests Acquired
Amendment Flag
Amendment Flag
Transaction Type
Transaction Type [Axis]
Transaction price, variable consideration from estimated future co-development billing
Variable Consideration Payment Received From Estimated Future Co Development Billing
Variable consideration payment received from estimated future co-development billing.
Transaction price, variable consideration from estimated future co-development billing
Schedule of Accrued and Other Current Liabilities
Schedule of Accrued Liabilities [Table Text Block]
Gross transaction price
Revenue Gross Transfer Price From Contract With Customer Excluding Assessed Tax
Revenue gross transfer price from contract with customer excluding assessed tax.
Restructuring charge.
Restructuring Charge [Policy Text Block]
Restructuring charge
Gross Unrealized Holding Losses
Gross Unrealized Holding Losses
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Manufacturing related milestone payment.
Manufacturing Related Milestone Payments
Manufacturing related milestone payments
Accounting Standards Update
Accounting Standards Update [Domain]
Collaboration Agreements, License Agreement and Revenues
Collaborative Arrangements License Agreement And Revenues Disclosure [Text Block]
Collaborative arrangements license agreement and revenues.
Proceeds from senior secured term loan facilities, net of issuance costs
Proceeds from Issuance of Secured Debt
Ownership percentage
Ownership Percentage
Equity Method Investment, Ownership Percentage
Amortization of right-of-use assets
Amortization of finance lease right-of-use assets
Finance Lease, Right-of-Use Asset, Amortization
Category of Item Purchased
Category of Item Purchased [Axis]
Purchases of available-for-sale securities
Payments to Acquire Debt Securities, Available-for-Sale
Purchases of available-for-sale securities
Leases [Abstract]
Available for sale securities in continual unrealized loss position, estimated fair value
Available for sale securities in continual unrealized loss position, estimated fair value
Debt Securities, Available-for-Sale, Unrealized Loss Position
Entity File Number
Securities Act File Number
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Transaction price and allocated to performance obligations
Transaction Price Allocated To Performance Obligations
Transaction price allocated to performance obligations.
Liability related to sale of future revenues.
Liability Related To Sale Of Future Revenues
Liability related to sale of future revenues - beginning balance
Liability related to sale of future revenues - ending balance
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Contract assets
Prepaid Supplies
Other Liabilities, Total
Other Liabilities
Due to related parties
Senior secured term loan facilities, non-current
Long-term debt, less current portion
Long-Term Debt, Excluding Current Maturities
Long-term Debt, Excluding Current Maturities, Total
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax
Unrealized gain (loss) on investments, net of tax effect
Increase in Deferred Revenue [Member]
Increase In Deferred Revenue [Member]
Increase in deferred revenue.
Cumulative Revenue
Cumulative Revenue License And Development Revenue Recognized
Total amount of revenue recognized for license and development services under the collaboration agreement as of a given date.
Share-Based Payment Arrangement [Abstract]
Schedule of Supplemental Cash Flow Information Related to Leases
Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block]
Schedule of supplemental cash flow information related to leases.
Juan Graham.
Juan Graham [Member]
Accounts Payable, Current, Total
Accounts Payable, Current
Accounts payable
Debt Instrument [Axis]
Total operating costs and expenses
Costs and Expenses
Accrued and other current liabilities ($45,870 and $39,814 to a related party)
Accrued Liabilities and Other Liabilities, Total
Accrued Liabilities and Other Liabilities
Expected term (in years)
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term
Collaborative Arrangement [Member]
Collaborative Arrangement [Member]
Percentage of outstanding shares owned
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage
Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023
Preferred Stock, Value, Issued, Ending Balance
Preferred Stock, Value, Issued, Beginning Balance
Preferred Stock, Value, Issued, Total
Preferred Stock, Value, Issued
Entity Small Business
Entity Small Business
Entity Shell Company
Entity Shell Company
Investment Type
Investment Type [Axis]
Contingent payment associated with business acquisition
Payment for Contingent Consideration Liability, Investing Activities
Percentage of joint development costs committed to fund
Percentage Of Funding For Costs
Represents the percentage of costs that will be funded by the other party under a collaborative agreement for development costs.
Additions
Contract With Customer Liability Additions
Contract with customer liability additions.
Commercial paper [Member]
Commercial Paper [Member]
Entity Address, Address Line One
Entity Address, Address Line One
Assets fair value disclosure
Cash and Cash Equivalents, Fair Value Disclosure
Contractual Obligation, Total
Outstanding non-cancelable purchase obligations
Contractual Obligation
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Manufacturing Costs
Burdened manufacturing costs
Antidilutive Securities [Axis]
Balance Sheet Components
Supplemental Balance Sheet Disclosures [Text Block]
Interest rate per annum
Debt Instrument, Interest Rate During Period
Subsequent Event Type [Domain]
Risk-free interest rate, minimum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Income Statement Location
Income Statement Location [Axis]
U.S./RoW and China [Member]
United States Rest Of World And China [Member]
United States/Rest of World and China.
Eluminex Agreements [Member]
Eluminex [Member]
License Agreement With Eluminex [Member]
License agreement with Eluminex.
Risk-free interest rate, maximum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Transfers of assets from level 1 to 2
Fair Value Assets Level1 To Level2 Transfer Amount
Fair value assets level1 to level2 transfer amount.
Cost, Product and Service [Extensible List]
Cost, Product and Service [Extensible Enumeration]
Geographic Distribution
Geographic Distribution [Domain]
Expected dividend yield
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Contract with Customer, Liability [Abstract]
Long-Term Debt, Type [Axis]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total
Net loss
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Level 2 [Member]
Fair Value, Inputs, Level 2 [Member]
Product [Member]
Product Revenue, Net [Member]
Product [Member]
Equity method investments
Equity method investment in unconsolidated variable interest entity
Beginning balance
Ending balance
Equity Method Investments
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Liability related to sale of future royalties.
Liability Related to Sale of Future Royalties [Abstract]
Risks and Uncertainties
Risks And Uncertainties Policy [Text Block]
Risks and uncertainties.
Principal of senior secured term loan facilities
Amount received
Long-Term Debt, Gross
Product and Service
Product and Service [Axis]
Deferred revenue, net of current ($2,343 and $9,705 to a related party)
Contract with Customer, Liability, Noncurrent
Deferred revenue, net of current
Astellas [Member]
Astellas [Member]
Astellas.
Title of 12(b) Security
Title of 12(b) Security
Foreign government bonds [Member]
Foreign Government Debt [Member]
Equity investments [Member]
Equity Securities [Member]
Money market funds
Money Market Funds, at Carrying Value
Payment period two.
Payment Period Two [Member]
Restructuring plan, expected reduction to workforce
Restructuring and Related Cost, Expected Number of Positions Eliminated
Fair Values of Financial Assets Measured on Recurring Basis
Fair Value, Assets Measured on Recurring Basis [Table Text Block]
Investments
Investments [Domain]
Accounting Standards Update
Accounting Standards Update [Axis]
Schedule of Investments [Table]
Impairment loss
Impairment Loss On Debt Securities Available For Sale
Impairment loss on debt securities available for sale.
Investing activities
Net Cash Provided by (Used in) Investing Activities [Abstract]
U.S. government bonds [Member]
U S Government Bonds [Member]
U.S. government bonds.
Subsequent Event [Table]
Schedule of Drug Product Revenue
Schedule Of Drug Product Revenue Table [Text Block]
Schedule of drug product revenue.
Increase (Decrease) in Inventories, Total
Inventories
Increase (Decrease) in Inventories
Balance at March 31, 2024
Balance at December 31, 2023
Contract with Customer, Liability, Total
Deferred revenues from associated contracts
Deferred revenue
Deferred Revenue
Contract with Customer, Liability
Commercial paper
Commercial Paper, at Carrying Value
Percentage of revenue sold.
Percentage of revenue sold
Percentage of revenue sold
Jeffrey Henderson.
Jeffrey Henderson [Member]
Interest expense
Interest Expense, Debt
Interest Expense, Debt, Total
Available for sale securities in continual unrealized loss position, gross unrealized holding losses
Available for sale securities in continual unrealized loss position, gross unrealized holding losses
Available for sale securities in continual unrealized loss position, gross unrealized holding losses
Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss
Delayed draw term loan two.
Delayed Draw Term Loan Two [Member]
Delayed Draw Term Loan 2
Common Stock, Shares, Outstanding, Ending Balance
Common Stock, Shares, Outstanding, Beginning Balance
Common stock, shares outstanding
Common Stock, Shares, Outstanding
Risk-free interest rate
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Stock-Based Compensation
Share-Based Payment Arrangement [Text Block]
Issuance costs and related transaction costs, amortised
Amortization of Debt Issuance Costs and Related Transaction Costs
Amortization of debt issuance costs and related transaction costs.
Gross revenue
Revenue Gross From Contract With Customer Excluding Assessed Tax
Revenue gross from contract with customer excluding assessed tax.
FibroGen Beijing [Member]
Fibro Gen Beijing [Member]
FibroGen Beijing.
Currency Translation and Other
Contract With Customer Liability Increase Decrease From Current Translation And Other
Contract with customer, liability, increase (decrease) from current translation and other.
Revenue payment cap amount.
Revenue Payment Cap Amount
Revenue payment cap amount
Income Statement Location
Income Statement Location [Domain]
Document Type
Document Type
Ownership [Axis]
Nonredeemable NCI [Member]
Nonconsolidated Investees, Other [Member]
Net Cash Provided by (Used in) Investing Activities
Net cash provided by investing activities
Document Quarterly Report
Document Quarterly Report
2014 Employee Share Purchase Plan [Member]
Share-Based Payment Arrangement [Member]
Counterparty Name [Domain]
Redeemable [Member]
Redeemable Preferred Stock [Member]
Product revenue from a related party
Product Revenue
Product revenue from a related party.
Net Cash Provided by (Used in) Financing Activities
Net cash provided by (used in) financing activities
Entity Filer Category
Entity Filer Category
Other than Temporary Impairment Losses, Investments
Impairment of investment
Balance Sheet Location
Balance Sheet Location [Domain]
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total
Foreign currency translation adjustments
Foreign currency translation adjustments
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax
Accrued Liabilities, Current [Abstract]
Short-term Investments, Total
Short-term investments
Short-Term Investments
Schedule of Activities of Liability Related to Sale of Future Revenues
Schedule of activity of liability related to sale of future revenues.
Schedule Of Activity Of Liability Related To Sale Of Future Revenues [Table Text Block]
Revenue Recognition Multiple Deliverable Arrangements [Table]
Revenue Recognition, Multiple-deliverable Arrangements [Table]
Interest income and other income (expenses), net
Interest income and other income (expenses), net
Nonoperating Income (Expense)
Roxadustat profit share to AstraZeneca
Accrued Profit Share Current
Accrued profit share current.
Total liabilities
Liabilities
Current portion of lease financing obligations
Current portion of lease financing obligations.
Total stockholders' deficit attributable to FibroGen
Stockholders' Equity Attributable to Parent, Ending Balance
Stockholders' Equity Attributable to Parent, Beginning Balance
Equity, Attributable to Parent
Net loss
Net loss
Interest and other, net
Nonoperating Income (Expense) [Abstract]
Interest Expense, Total
Interest expense
Interest Expense
Proceeds from Issuance Initial Public Offering
Proceeds from issuance of common stock under ATM Program, net of commissions
Geographic Distribution
Geographic Distribution [Axis]
Contract with Customer, Asset, after Allowance for Credit Loss, Current, Total
Contract with Customer, Asset, after Allowance for Credit Loss, Current
Contract asset
Bulk Drug Product [Member]
Bulk drug product.
Manufacture and Supply of Roxadustat [Member]
Manufacture And Supply Of Roxadustat [Member]
Manufacture and Supply of Roxadustat.
Award Date [Axis]
Statement of Financial Position [Abstract]
Diluted
Diluted
Diluted
Weighted Average Number of Shares Outstanding, Diluted
Investment Gain Loss In Unconsolidated Variable Interest Entity
Investment (gain) loss in unconsolidated variable interest entity.
Investment income in unconsolidated variable interest entity
Leases
Leases.
accrued litigation settlement.
Accrued Litigation Settlement
Accrued litigation settlement
Amortized Cost
Amortized Cost
Debt Securities, Available-for-Sale, Amortized Cost
Accrued interest for finance lease liabilities
Increase Decrease In Accrued Interest For Finance Lease Liabilities
Increase (decrease) in accrued interest for finance lease liabilities.
Use of Estimates
Use of Estimates, Policy [Policy Text Block]
Income Taxes
Income Tax Disclosure [Text Block]
Accounting Policy [Table]
Accounting Policy [Table]
Accounting policy.
Other Purchases [Member]
Other Purchases [Member]
Other Purchases.
Summary of Reconciliation of Basic and Diluted Net Income (Loss) Per Share Calculation
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale
Other-than-temporary impairment loss
Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Total
Liability related to sale of future revenues current.
Liability Related To Sale Of Future Revenues Current
Current portion of liability related to sale of future revenues
Valuation Approach and Technique [Axis]
Disaggregation Of Revenue [Line Items]
Disaggregation of Revenue [Line Items]
Available for sale securities in continual unrealized loss position, 12 months or more, gross unrealized holding losses
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Fair Value Disclosures [Abstract]
Level 1 [Member]
Fair Value Hierarchy and NAV [Axis]
Measurement Frequency
Measurement Frequency [Domain]
License and Development [Member]
License And Development [Member]
License and development.
Payments to Acquire Property, Plant, and Equipment, Total
Purchases of property and equipment
Payments to Acquire Property, Plant, and Equipment
Reclassified to Accrued Liability
Contract With Customer Liability Reclassified to Accrued Liability
Contract with customer liability reclassified to accrued liability.
Foreign subsidiaries [Member]
Geographic Distribution, Foreign [Member]
Sales To Falikang [Member]
Sales To Falikang [Member]
Sales to Falikang.
Stock Issued During Period, Shares, New Issues
Issuance of common stock under ATM Program shares
Employee-related Liabilities, Current, Total
Payroll and related accruals
Employee-related Liabilities, Current
Business Acquisition
Business Acquisition [Axis]
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total
Total cash and cash equivalents at beginning of period
Total cash and cash equivalents at end of period
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
Cumulative catch-up net adjustment
Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Modification of Contract
Income Tax Disclosure [Abstract]
Finite-Lived Intangible Assets by Major Class
Finite-Lived Intangible Assets by Major Class [Axis]